Kurma Partners Completes First Close of EUR 250 Million Biofund IV

Kurma Partners has announced the initial close of its latest fund, Biofund IV, securing EUR 140 million towards its EUR 250 million target. The fund aims for completion by 2025. Biofund IV is set to support 16 to 20 ventures, with an emphasis on innovative therapeutic development. Kurma has already launched investments in companies such as SciRhom and Avidicure.

Building on successes from Biofund III, Kurma plans to leverage its extensive networks and collaborative strategies. Early backers of Biofund IV include Eurazeo, Bpifrance, and CSL, among other undisclosed partners. These strategic partnerships underscore confidence in Kurma’s ability to transform scientific advancements into market-ready solutions.